BRCA2

US Preventive Services Task Force recommends genetic testing for mutations in the cancer-related genes for more—but not all—women.

Its screen for selected variants of some disease-linked genes gives customers an incomplete picture of their risk—do they know?

A neurologist by training, Stefánsson founded Iceland-based deCODE Genetics to explore what the human genome can tell us about disease and our species’ evolution.

With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.

The agency gave personal genomics company 23andMe the green light to screen samples for breast cancer–related genetic mutations.

Researchers identify 72 novel genetic variants associated with breast cancer risk.

Members of the BabySeq Project discuss trial enrollment, preliminary findings.

Color Genomics announces a new, lower-cost BRCA mutation test, while Inserm and Quest Diagnostics reveal plans to pool patient data to investigate rare mutations.

In a large study, researchers find evidence to suggest that the type and location of a woman’s BRCA1/2 mutations may affect her cancer risk.

Myriad Genetics, the company originally behind tests for the cancer-associated BRCA mutations, is suing another competitor for patent infringement.

August 2013's selection of notable quotes

Myriad Genetics, the company originally behind tests for the cancer-associated BRCA mutations, is suing two competitors for patent infringement.

Last week’s Supreme Court decision to invalidate patents on human genes was a win for patients, independent researchers, and even the wider biotech industry.

The Justices have decided that isolated sequences of human DNA are not eligible for patent protection, but rules that artificial sequences can be patented.
 

As reproductive tissues age, DNA repair mechanisms become less efficient, causing genomic damage to accumulate.

The Supreme Court agrees to hear a case deciding if two cancer genes should continue to be protected by patent.

Myriad Genetics can hold patents on the BRAC1 and BRAC2 oncogenes, but not on tests comparing DNA sequences.

A public interest legal group has renewed the fight against DNA patenting.